ArticleFrontiers in oncology2025
A case report of multiple primary malignant tumors: breast cancer and colorectal cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer and colorectal cancer are both common malignant tumors worldwide. This report describes a case of multiple primary malignant tumors (MPMT) in a 52-year-old female patient diagnosed successively with right breast triple-negative breast cancer (T2N1M0, stage IIb) and rectal moderately differentiated adenocarcinoma (pT3N0M0, stage IIa). Through a multidisciplinary team (MDT) approach, we developed a treatment strategy involving breast-conserving surgery for the breast cancer followed by laparoscopic radical resection for the rectal cancer. Postoperative sequential therapy comprised TP chemotherapy (albumin-bound paclitaxel plus carboplatin), radiotherapy, and capecitabine. The patient developed Grade IV bone marrow suppression during chemotherapy, which improved after aggressive supportive care. The patient is currently in disease remission. This case highlights the importance of multidisciplinary collaboration, genetic risk assessment, individualized treatment decisions, comprehensive tumor management, and robust supportive care in the diagnosis and treatment of multiple primary malignant tumors, providing valuable insights for managing similar clinical cases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.